Gait Characteristics in CIDP
Patients with CIDP demonstrate a characteristic slow, cautious gait pattern marked by shorter stride length, prolonged cycle time, increased double support time, and increased variability in stride length and swing time compared to healthy controls 1.
Core Gait Abnormalities
The most consistent and clinically significant gait disturbances in CIDP include:
- Shorter stride length (SL) - patients take smaller steps
- Prolonged cycle time (CT) - slower overall walking speed
- Increased double support time (DS) - both feet remain on ground longer, reflecting compensatory strategy for instability
- Increased variability in stride length and swing time - this variability is particularly concerning as it suggests potential risk for instability and falls 1
These abnormalities persist across all walking conditions, including basic walking, dual-motor tasks, dual-mental tasks, and combined tasks 1.
Clinical Severity Correlates
Patients with CIDP and concurrent diabetes demonstrate more severe gait abnormalities, including more proximal weakness and more pronounced gait disturbance compared to CIDP patients without diabetes 2. This is important to recognize as the clinical phenotype differs based on comorbidities.
The severity of gait impairment correlates with:
- Higher vibration perception thresholds
- Higher Toronto Clinical Neuropathy Scores
- More abnormal nerve conduction studies
- Greater overall disability 2
Functional Impact
Gait dysfunction is among the most salient and bothersome manifestations of CIDP from the patient perspective 3. Walking difficulties profoundly impact:
- Physical functioning and activities of daily living
- Work capacity
- Social participation
- Overall quality of life 4, 3
Quality of life in CIDP patients correlates directly with gait performance as measured by 40-meter walk tests and 6-spot step tests 4.
Treatment Response Monitoring
Gait parameters serve as sensitive outcome measures for treatment response. Following intravenous immunoglobulin (IVIg) treatment, patients show significant improvements in:
- Gait velocity (most statistically significant)
- Cadence
- Stride length
- Double support time
- Stance phase (highly significant in responders)
- Swing phase (highly significant in responders) 5
During follow-up, changes in cycle time and its variation during combined tasks significantly differentiate patients with improved versus non-improved disability scores 1. Specifically, shorter cycle time duration and less cycle time variation correlate with disability improvement 1.
Clinical Pitfalls
A common pitfall is underestimating gait dysfunction severity in CIDP patients with diabetes, who paradoxically are less likely to receive disease-modifying immunotherapy despite having more severe clinical and electrophysiological neuropathy 2. However, these patients have similar treatment response rates to those without diabetes, so diabetes status should not preclude aggressive treatment 2.
The increased variability in stride parameters represents an often-overlooked fall risk that requires specific attention in rehabilitation planning 1.